profit from every $100 of sales.
$0$100
Dogwood Therapeutics
$1.12-5.08% today
-80.8% in 1 year
1-year low $1.031-year high $6.82
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Dogwood Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$34.3 million of profit last year.
SalesProfit
Dogwood Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Dogwood Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Dogwood Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -12 | -5 | -12 | -28 | |
| -12 | -5 | -12 | -28 | |
| -12 | -5 | -12 | -34 | |
| -27.75 | -7.00 | -12.52 | -7.13 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 8 | 4 | 94 | 90 |
| Cash | 7 | 3 | 15 | 7 |
| Total debt | – | 0 | 16 | 0 |
| Total liabilities | 1 | 0 | 30 | 15 |
| 7 | 4 | 64 | 75 | |
| 0 | 1 | 1 | 5 | |
| -132.8% | -113.0% | -12.1% | -29.4% | |
| -167.2% | -139.1% | -19.2% | -45.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -11 | -5 | -9 | -16 | |
| – | – | – | – | |
| -11 | -5 | -9 | -16 | |
| Dividends paid | – | – | – | – |
| – | 0 | 0 | 0 | |
| 1 | 1 | 0 | 0 |
Valuation
- –
- –
- –
- 0.8×
- –
- –
- 0.3×
- -36.5%
- -80.0%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -30.9%
- -95.5%
- -35.9%
- -29.7%
- -30.9%
- –
Growth
- –
- –
- −77.7%
- –
- +122.9%
Financial health
- 0.5×
- 0.00
- 0.2%
- –
- 5.86
- 5.86
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 15%of 952
Bottom 20%of 883
Bottom 1%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.15 | -0.22 | +31.8% |
| Mar 18, 2026 | -0.26 | -0.86 | +69.8% |
| Nov 6, 2025 | -8.20 | -1.23 | −566.7% |
| Aug 13, 2025 | -1.99 | -1.26 | −57.9% |
| May 8, 2025 | -4.21 | -0.77 | −446.8% |
| Feb 26, 2025 | -5.90 | -1.36 | −333.6% |
| Nov 7, 2024 | -2.05 | -1.18 | −73.7% |
| Aug 8, 2024 | -0.05 | -0.07 | +28.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
70Pass
Philip Fisher
32No pass
Peter Lynch
60Pass
Joel Greenblatt
40No pass
Charlie Munger
21No pass
Terry Smith
20No pass
Questions about Dogwood Therapeutics
Is Dogwood Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Dogwood Therapeutics AI analysis
What does Dogwood Therapeutics do?
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. It is in Biotechnology.
Does Dogwood Therapeutics pay a dividend?
No. Dogwood Therapeutics does not pay a dividend at the moment.
Is Dogwood Therapeutics stock halal?
Yes. Dogwood Therapeutics passes our halal screen: its business is permitted and its debt is 0.4% of its market value, under the 30% limit. How we check
How has Dogwood Therapeutics stock done over the past year?
Down 80.8% over the past twelve months, to $1.12. It traded between $1.03 and $6.82 and is 83.6% below its high.
Who are Dogwood Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Dogwood Therapeutics's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.